Videregen — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Videregen is a clinical-stage biotechnology company pioneering tissue-engineered airway replacements. Its core technology involves a proprietary, biocompatible scaffold that is seeded with a patient's own stem cells to create a personalized, living implant designed to integrate with native tissue. The company's lead product candidate, a tissue-engineered trachea, is advancing through clinical development to address a significant unmet need in reconstructive surgery. Founded in 2012 and based in Manchester, Videregen operates as a private company, leveraging strategic partnerships and grant funding to advance its pipeline.

OtolaryngologyPulmonologyReconstructive Surgery

Technology Platform

Proprietary tissue engineering platform combining a patient-specific, biocompatible synthetic scaffold with the patient's own seeded mesenchymal stem cells (MSCs) to create living, implantable hollow organs.

Opportunities

Addressing a severe unmet need with no effective standard of care for long-segment tracheal defects, allowing for a high-value proposition.

Successful clinical validation of the trachea implant would de-risk the platform for expansion into larger markets involving other hollow organs like the esophagus or bowel.

Growing regulatory familiarity with advanced therapy medicinal products (ATMPs) may create a clearer pathway to approval.

Risk Factors

Clinical and regulatory pathway for a first-in-class tissue-engineered organ is complex and uncertain, requiring demonstration of long-term safety and functional integration.

The autologous, patient-specific manufacturing model is inherently complex, costly, and difficult to scale reliably.

Securing reimbursement for a high-cost, novel surgical implant from healthcare payers presents a significant commercialization hurdle.

Competitive Landscape

Direct competition is limited due to the highly specialized nature of the indication, but alternatives include high-risk surgical techniques, cadaveric transplants, and permanent stents. Videregen faces potential future competition from other tissue engineering or 3D bioprinting companies developing hollow organ replacements. The primary competitive challenge is less from other products and more from establishing clinical proof-of-concept and changing surgical practice.

More companies in Regenerative Medicine →More companies in United Kingdom →